A Multi-Center Phase 1b Pharmacokinetic and Radiation Dosimetry Study Evaluating 99mTc-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)

Trial Profile

A Multi-Center Phase 1b Pharmacokinetic and Radiation Dosimetry Study Evaluating 99mTc-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2015

At a glance

  • Drugs Tc 99m ethylenedicysteine deoxyglucose (Primary) ; Fludeoxyglucose F-18
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors CellPoint
  • Most Recent Events

    • 26 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top